drugset / Trial / NCT00605020

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT00605020

Phase 3 Completed 719 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of an intensified treatment regimen with preprandial insulin aspart and insulin detemir once or twice daily to a more convenient regimen with biphasic insulin aspart 30 twice daily on blood glucose control in subjects with type 2 diabetes.

Timeline

Start
2003-12-02
Primary completion
2005-03-03
Completion
2005-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart Protein / enzyme biologic
Subject insulin aspart Protein / enzyme biologic
Subject insulin detemir Protein / enzyme biologic